Congenital Adrenal Hyperplasia

What Is Congenital Adrenal Hyperplasia?

Congenital Adrenal Hyperplasia (CAH) is an autosomal recessive hereditary disorder caused by deficient key enzymes in adrenal cortical hormone biosynthesis. Its core pathological feature is impaired cortisol synthesis. Reduced cortisol releases negative feedback suppression of the hypothalamic-pituitary-adrenal (HPA) axis, driving compensatory over-secretion of adrenocorticotropic hormone (ACTH). Excess ACTH stimulates adrenal cortical hyperplasia and abnormal accumulation of androgen precursors.

The overall incidence of CAH among newborns ranges from 1 in 10,000 to 1 in 20,000. 21-hydroxylase deficiency (21-OHD) caused by pathogenic variants in the CYP21A2 gene accounts for 90%–95% of all CAH cases, making it the most prevalent subtype.

Based on clinical severity, CAH is classified into classic CA (salt-wasting form and simple virilizing form) and non-classic CA. Typical clinical manifestations include neonatal salt-wasting crisis (vomiting, dehydration, electrolyte disturbances), virilization of female external genitalia, pseudoprecocious puberty in males, accelerated childhood growth with ultimately short adult stature.

Pathogenesis

CAH originates from enzymatic defects in the adrenal steroidogenesis pathway.

Under physiological conditions, cholesterol is transported into the inner mitochondrial membrane via steroidogenic acute regulatory protein (StAR), then converted to pregnenolone catalyzed by cholesterol side-chain cleavage enzyme (CYP11A1). Subsequent synthetic pathways diverge across distinct adrenal cortical zones:

1. Zona glomerulosa: Lacks CYP17A1; pregnenolone is sequentially catalyzed by HSD3B2, CYP21A2 and CYP11B2 to generate aldosterone.
2. Zona fasciculata: CYP17A1 exerts 17α-hydroxylase activity to convert precursors into 17-hydroxyprogesterone (17-OHP), which undergoes sequential reactions with HSD3B2, CYP21A2 and CYP11B1 to produce cortisol.
3. Zona reticularis: The 17,20-lyase activity of CYP17A1 is markedly enhanced with the cofactor cytochrome b5 (CYB5A), converting precursors into dehydroepiandrosterone (DHEA) and androstenedione, which are further metabolized into androgens.

Figure Source: Adrenal Steroidogenesis and Congenital Adrenal Hyperplasia

21-hydroxylase deficiency (21-OHD), the most common CAH subtype, arises from loss-of-function mutations in CYP21A2 that drastically reduce or eliminate 21-hydroxylase activity. This enzyme is essential for aldosterone and cortisol synthesis, mediating conversion of progesterone to 11-deoxycorticosterone and 17-OHP to 11-deoxycortisol. Loss of enzyme function blocks both downstream synthetic routes, resulting in severe cortisol and aldosterone insufficiency.

Low cortisol removes negative feedback restraint on the HPA axis, triggering sustained excessive ACTH secretion and compensatory adrenal hyperplasia. Meanwhile, blocked canonical metabolic pathways cause massive buildup of precursor substrates (predominantly 17-OHP). These accumulated intermediates are shunted into intact androgen synthetic cascades and converted via multi-step enzymatic reactions (including CYP17A1) into androstenedione, then potent testosterone, leading to the characteristic clinical phenotype of CAH.

Figure Source: Adrenal Steroidogenesis and Congenital Adrenal Hyperplasia

Gene Therapy Strategies

1. Gene Replacement Therapy

Adeno-associated viral (AAV) vectors deliver functional wild-type CYP21A2 to restore deficient enzyme activity. Intravenous or local vector administration drives ectopic 21-hydroxylase expression in the adrenal glands or liver. AAV5-CYP21A2 (BBP-631) has advanced into Phase I/II clinical trials.

2. Gene Editing Therapy

Precision gene editing directly corrects pathogenic CYP21A2 variants in patient genomes. Permanent gene function restoration is achieved via in-situ mutation repair or transgene integration at safe harbor genomic loci.

Preclinical Mouse Models for CAH Research

1. Cyp21a2^-/- Knockout Mice Complete ablation of the murine Cyp21a2 gene. Animals develop severe corticosterone deficiency (<10% of wild-type levels) within weeks after birth, accompanied by drastically elevated 17-OHP. Aldosterone initially rises as a compensatory response then declines, leading to salt wasting. Adrenal glands enlarge 3–5 fold; most mice succumb at 4–8 weeks of age, faithfully recapitulating human salt-wasting CAH.
2. Cyp21a2^R484Q Knock-In Mice Carry the R484Q pathogenic point mutation. Corticosterone is moderately reduced (30–50% normal), with 5–20 fold elevated 17-OHP and mild adrenal hyperplasia (1.5–2 fold enlargement). Mice survive to adulthood but exhibit growth retardation and reduced female fertility, modeling simple virilizing CAH.
3. Cyp21a2^I173N Knock-In Mice Harbor the I173N variant with mild corticosterone reduction (50–70% baseline). Basal 17-OHP is slightly elevated and surges significantly upon ACTH stimulation, with negligible adrenal enlargement. Animals have normal lifespan and recapitulate non-classic CAH or carrier phenotypes.

VeloGene Biotechnology Accelerates Rare Disease Gene Therapy R&D

Gene therapy delivers transformative therapeutic prospects for rare endocrine inherited disorders, yet preclinical mechanistic research and therapeutic efficacy validation fully rely on standardized, well-characterized animal models.

Powered by our proprietary TurboMice™ technology, VeloGene Biotechnology resolves two longstanding technical bottlenecks of traditional transgenic strain construction: prolonged breeding cycles and low success rates for complex multi-locus genetic modifications. The platform supports precise editing of nearly any target genomic locus and generates fully homozygous gene-edited mouse lines directly from embryonic stem cells in as little as 2 months.

VeloGene Biotechnology provides custom congenital adrenal hyperplasia mouse models including Cyp21a2^-/- knockout mice, Cyp21a2^R484Q knock-in mice and Cyp21a2^I173N knock-in mice. Academic and industrial investigators are welcome to contact our technical team for project consultations!